Navigation Links
VisEn Launches New VivoTag(R) 645 Fluorescence Molecular Imaging Label
Date:5/5/2010

BEDFORD, Mass., May 5 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence imaging from research through medicine, announced today the commercial launch of its new VivoTag® 645 red fluorescent dye for optimized labeling of biomolecules in a broad range of in vitro and in vivo research applications.  

The new VivoTag 645 represents VisEn's first agent offering in the lower-red wavelengths, enabling optimized and integrated imaging applications in both in vivo and in vitro research areas.  The VivoTag 645 is specifically designed for efficient and robust labeling of biomolecules, and is optimized for broad in vitro and in vivo imaging performance, including system compatibility, superior brightness, biocompatibility and stability in biological environments.  

"Our new VivoTag 645 represents an important evolution in our fluorescent imaging agent product line," said Kirtland Poss, President and CEO of VisEn Medical. "This new label is designed to be well-suited for applications both in vitro and in vivo research and we look forward to working closely with our customers in continually advancing these integrated research areas."

The new VivoTag 645 is particularly well suited for labeling and imaging of proteins, antibodies, and small molecules in a range of research areas.  The fluorescence wavelength is matched for biological imaging applications on in vitro and in vivo fluorescence systems, including advanced microscopes, high content imaging and flow cytometry systems. It is also optimized for use with VisEn's fluorescence tomography FMT™ imaging systems which also have expanded wavelength capabilities to enable quantitative imaging of up to four channels and four different biomarkers of interest in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts.  VisEn offers over 35 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, GastroSense™, ReninSenseTM, Annexin-VivoTM, and the FAST™ line of imaging agents including Cat K FAST™ and Cat B FAST™.  VisEn also offers specialized lines of agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes and its NanoSpark® nanoparticles for customized fluorescence agent labeling.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including in vitro, cell, tissue and in vivo imaging applications.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and other cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking preclinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its RED Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific preclinical and clinical research areas. Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent
2. VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
3. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
4. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
5. VisEn Medical Raises $7 Million in Series B Financing
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. BellBrook Labs Launches Compound Profiling Services with High Content 3D Invasion Assay
8. Ansell Launches Worldss First Antimicrobial Surgical Glove
9. ChromaDex Launches pTeroPure Pterostilbene
10. Vermont Launches Renewable Energy Atlas
11. DNA-Planet Launches New Service for Customer-Individual Indirect DNA Paternity Testing and Kinship Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... philosopher Koert van Mensvoort - founder of the Next Nature Network ... - has written a ,Letter to Humanity, in support of International ... slave and victim to its own technology, but to employ technology to enhance ... ... founder of the Next Nature Network and Fellow of ‘Next Nature’ at the ...
(Date:4/19/2017)... ... ... A number of new instruments have recently emerged to accommodate different applications ... and Cell Analysis Education Webinar Series , will focus on advances in the Invitrogen™ ... applications. , Many flow cytometers have unique capabilities and the Attune NxT Flow ...
(Date:4/19/2017)... ... April 19, 2017 , ... ThermaGenix, the ... This event adds to several other early achievements at ThermaGenix, including the business ... , ThermaGenix will use proceeds from the Series A-1 round to:, ...
(Date:4/19/2017)... Calif. , April 19, 2017  As ... Drug Abuse and Heroin Summit ,  Proove® Biosciences, ... study analyzing genetics, environmental, and lifestyle factors to ... from the University of Southern California (USC), the ... , and Proove publish results showing that Proove ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):